Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

In an interview with Targeted Oncology, Matthew Manning, MD, FASTRO, discussed the many radiation oncology tasks that have been improved with AI and its prospective utility in cancer diagnosis and treatment decisions.

Sara Hurvitz, MD, discusses recent updates for selective estrogen receptor degraders in the treatment of patients with metastatic breast cancer and how it has impacted clinical decisions.